DCGI recommends Covovax as heterologous booster dose for those who got 2 doses of Covishield, Covaxin
New Delhi, January 12: Drugs Controller General of India (DCGI) has recommended market authorisation for Serum Institute of India's Covid vaccine Covovax as a heterologous booster dose for those who have already taken both doses of Covishield or Covaxin.
Previously, DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, for children aged 12 to 17 on March 9, 2022, and for children aged 7 to 11 on June 28, 2022, subject to certain conditions.
Covovax is manufactured by a technology transfer from Novavax. It has received conditional marketing authorization from the European Medicines Agency.
Also Read | IMD predicts second cold wave in Delhi, parts of north India from January 14
On December 17, 2021, the World Health Organization (WHO) granted it an emergency-use listing.
The Government of India recently approved Bharat Biotech's nasal Covid vaccine for adults over the age of 18 for use as a heterologous booster dose.
Also Read | Coachella 2023: Diljit Dosanjh all set to perform at one of largest music festivals in US
- ANI
